Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 8/20 | 0.40 |
| ▸ | NPY1R | P25929 | 5/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881429 | 0.88 | NPY4R (0.51) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL6368164 | 0.86 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL6368171 | 0.86 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1521349 | 0.86 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL23626315 | 0.84 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL23610947 | 0.84 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2304732 | 0.83 | DPP7 (0.56) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL13062154 | 0.83 | DPP7 (0.56) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL25677222 | 0.82 | CACNA1B (0.36) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19371883 | 0.81 | DPP7 (0.63) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165964-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORP (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165964-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORP (US) | 2023-06-01 | — | — | US | disclosed |
| US-11529420-B2 | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same | DURECT CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210038731-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORPORATION (US) | 2021-02-11 | — | — | US | disclosed |
| US-10758623-B2 | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same | DURECT CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORPORATION (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165964-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | PAICS, PARG, PUF60 | DPP7 2424/4885GNAI3 2350/4885GNAO1 3111/4885 |
| US-11529420-B2 | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same | PAICS, PARG, PUF60 | DPP7 2424/4885GNAI3 2350/4885GNAO1 3111/4885 |
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | PAICS, PARG, PUF60 | DPP7 2424/4885GNAI3 2350/4885GNAO1 3111/4885 |
| US-20210038731-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | PAICS, PARG, PUF60 | DPP7 2424/4885GNAI3 2350/4885GNAO1 3111/4885 |
| US-10758623-B2 | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same | PAICS, PARG, PUF60 | DPP7 2424/4885GNAI3 2350/4885GNAO1 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.